Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D018771:Arthralgia / Q000188:drug therapy; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000068579:Celecoxib; D065729:Cytochrome P-450 CYP2C9; D004347:Drug Interactions; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D019934:International Normalized Ratio; D011110:Polymorphism, Genetic; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects*; D014859:Warfarin / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D011720:Pyrazoles; D013449:Sulfonamides; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000068579:Celecoxib